Company profile
Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05651022 | phase1_2 | active_not_recruiting | 2023-02-28 | 2027-06-30 | Indaptus Therapeutics, Inc | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors |
FDA applications (0)
No records yet.